City Research Online

Certolizumab pegol (CDP870) for rheumatoid arthritis in adults

Ruiz Garcia, V., Burls, A., Cabello Lopez, J. C. L., Fry-Smith, A., Munoz, J. G. G., Jobanputra, P. and Saiz Cuenca, E. S. C. (2009). Certolizumab pegol (CDP870) for rheumatoid arthritis in adults. Cochrane Database of Systematic Reviews(1), CD007649. doi: 10.1002/14651858.CD007649.pub2


This is the protocol for a review and there is no abstract. The objectives are as follows:

To determine the efficacy and safety of certolizumab pegol (CDP870) and if it has clinical benefits for people with rheumatoid arthritis (RA) who do not respond well to conventional disease-modifying anti-rheumatic drugs (DMARDs).

Publication Type: Article
Subjects: R Medicine > RC Internal medicine
Departments: School of Health Sciences
Date Deposited: 11 Sep 2017 13:49
Text - Published Version
Download (163kB) | Preview



Downloads per month over past year

View more statistics

Actions (login required)

Admin Login Admin Login